Education
About Us
Working with TipRanks
Follow Us
Atara Biotherapeutics Inc (ATRA)
:ATRA
ATRA Stock Chart & Stats
$15.79
-$1.12(-6.68%)
At close: 4:00 PM EST
$15.79
-$1.12(-6.68%)
Day’s Range― - ―
52-Week Range$5.01 - $18.71
Previous CloseN/A
Volume32.09K
Average Volume (3M)70.73K
Market Cap
$126.76M
Enterprise Value$239.26M
Total Cash (Recent Filing)$13.71M
Total Debt (Recent Filing)$58.60M
Price to Earnings (P/E)7.8
Beta0.60
Next Earnings
Mar 02, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding7,210,235
10 Day Avg. Volume84,369
30 Day Avg. Volume70,732
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.02
Price to Sales (P/S)0.77
P/FCF Ratio-1.45
Enterprise Value/Market Cap1.89
Enterprise Value/Revenue1.57
Enterprise Value/Gross Profit1.93
Enterprise Value/Ebitda7.85
Forecast
1Y Price Target
$17.50Price Target Upside10.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.55
Revenue Forecast (FY)$121.29M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAtara recorded a significant improvement in financial results for 2Q25, with net earnings per share far exceeding prior forecasts.
Milestone PaymentApproval of tab-cel will trigger a $40M milestone, providing much-needed cash that could restart Atara's allogeneic CAR T program for autoimmune disease.
Regulatory ApprovalAnalyst remains optimistic about the likelihood of FDA approval for tab-cel, as EBV+ PTLD is an ultra-rare indication and Atara has been able to address manufacturing concerns raised by the FDA.
Bears Say
Investment CaseDespite developments with tab-cel, the analyst does not see a compelling investment case at this time and reiterates a Neutral rating without a price target.
Regulatory RisksRisks include the potential rejection of the tab-cel BLA resubmission by the FDA and setbacks with other pipeline candidates.
Atara Biotherapeutics News
ATRA FAQ
What was Atara Biotherapeutics Inc’s price range in the past 12 months?
Atara Biotherapeutics Inc lowest stock price was $5.00 and its highest was $18.70 in the past 12 months.
What is Atara Biotherapeutics Inc’s market cap?
Atara Biotherapeutics Inc’s market cap is $126.76M.
When is Atara Biotherapeutics Inc’s upcoming earnings report date?
Atara Biotherapeutics Inc’s upcoming earnings report date is Mar 02, 2026 which is in 74 days.
How were Atara Biotherapeutics Inc’s earnings last quarter?
Atara Biotherapeutics Inc released its earnings results on Nov 29, 2025. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.666 by $0.346.
Is Atara Biotherapeutics Inc overvalued?
According to Wall Street analysts Atara Biotherapeutics Inc’s price is currently Undervalued.
Does Atara Biotherapeutics Inc pay dividends?
Atara Biotherapeutics Inc does not currently pay dividends.
What is Atara Biotherapeutics Inc’s EPS estimate?
Atara Biotherapeutics Inc’s EPS estimate is -0.27.
How many shares outstanding does Atara Biotherapeutics Inc have?
Atara Biotherapeutics Inc has 7,210,235 shares outstanding.
What happened to Atara Biotherapeutics Inc’s price movement after its last earnings report?
Atara Biotherapeutics Inc reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.666. Following the earnings report the stock price went up 11.822%.
Which hedge fund is a major shareholder of Atara Biotherapeutics Inc?
Currently, no hedge funds are holding shares in ATRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atara Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (10.83% Upside)
$17.50 (10.83% Upside)
Blogger Sentiment
Bullish
ATRA Sentiment 70%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 70.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $614.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-78.86%
Trailing 12-Months
Company Description
Atara Biotherapeutics Inc
Atara Biotherapeutics (ATRA) is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients with serious diseases, particularly cancer and autoimmune disorders. The company operates primarily in the biopharmaceutical sector, leveraging advanced science to create T-cell therapies that harness the body's immune system to target and eradicate disease. Atara's core products include its lead investigational therapies, which utilize allogeneic T-cell immunotherapy derived from donor cells, aimed at treating various malignancies and chronic viral infections.
ATRA Stock 12 Month Forecast
Average Price Target
$17.50
▲(10.83% Upside)
Technical Analysis
MacroGenics
―
Adverum Biotechnologies
―
Zentalis Pharmaceuticals
―
Surrozen
―
TScan Therapeutics
―
Ownership Overview
41.91% Insiders
5.80% Mutual Funds
15.43% Other Institutional Investors
34.16% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---